• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一名长期机械通气患者因血管紧张素转换酶抑制剂诱发的危及生命的支气管痉挛:诊断陷阱与文献综述

Life-threatening bronchospasm induced by an angiotensin-converting enzyme inhibitor in a chronically ventilated patient: Diagnostic pitfalls and literature review.

作者信息

Marcus Esther-Lee, Hush Amir, Atrash Hisham, Shibli Roaia, Heyman Samuel N

机构信息

Long-Term Respiratory Care Division, Herzog Medical Center; Faculty of Medicine Hebrew University of Jerusalem Jerusalem Israel.

Department of Medicine Hadassah-Hebrew University Hospital, Mt. Scopus Jerusalem Israel.

出版信息

Respirol Case Rep. 2023 Sep 20;11(10):e01224. doi: 10.1002/rcr2.1224. eCollection 2023 Oct.

DOI:10.1002/rcr2.1224
PMID:37744527
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10511829/
Abstract

Cough- and asthma-like symptoms are common adverse reactions to angiotensin-converting enzyme inhibitors (ACEi). However, attributing these symptoms to the use of ACEi might be masked by clinical confounders. We report a 68-year-old female residing in a long-term acute-care facility for patients requiring prolonged invasive mechanical ventilation treated for years with ACEi. Daily reversible bouts of life-threatening severe bronchospasm gradually developed over 6 weeks and abruptly resolved following the cessation of ACEi treatment. The late appearance of bronchospasm and the unique clinical setup of chronic invasive ventilation in a patient with smoking-related chronic obstructive lung disease are among the principal confounders that delay the identification of the causative association between ACEi and respiratory compromise. Chronic positive pressure ventilation may also conceal small airway reactivity and obstruction, similar to auto-positive end-expiratory pressure (auto-PEEP). Conceivably, angiotensin receptor blockers should be preferred over ACEi in such patients.

摘要

咳嗽和哮喘样症状是血管紧张素转换酶抑制剂(ACEi)常见的不良反应。然而,这些症状与ACEi使用之间的关联可能会被临床混杂因素所掩盖。我们报告了一名68岁女性,她居住在一家长期急性护理机构,因需要长期有创机械通气而接受ACEi治疗多年。在6周内逐渐出现每日发作的、可逆转的危及生命的严重支气管痉挛,在停用ACEi治疗后症状突然缓解。支气管痉挛的迟发性出现以及吸烟相关慢性阻塞性肺疾病患者慢性有创通气的独特临床情况,是延迟识别ACEi与呼吸功能损害之间因果关系的主要混杂因素。慢性正压通气也可能掩盖小气道反应性和阻塞,类似于内源性呼气末正压(auto-PEEP)。可以想象,在此类患者中,血管紧张素受体阻滞剂应优于ACEi。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca9d/10511829/435af99c3a5a/RCR2-11-e01224-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca9d/10511829/435af99c3a5a/RCR2-11-e01224-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca9d/10511829/435af99c3a5a/RCR2-11-e01224-g001.jpg

相似文献

1
Life-threatening bronchospasm induced by an angiotensin-converting enzyme inhibitor in a chronically ventilated patient: Diagnostic pitfalls and literature review.一名长期机械通气患者因血管紧张素转换酶抑制剂诱发的危及生命的支气管痉挛:诊断陷阱与文献综述
Respirol Case Rep. 2023 Sep 20;11(10):e01224. doi: 10.1002/rcr2.1224. eCollection 2023 Oct.
2
[Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].[氯化乙酰甲胆碱支气管激发试验标准技术规范(2023年)]
Zhonghua Jie He He Hu Xi Za Zhi. 2024 Feb 12;47(2):101-119. doi: 10.3760/cma.j.cn112147-20231019-00247.
3
Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors.与血管紧张素转换酶抑制剂治疗相关的呼吸困难、哮喘和支气管痉挛。
BMJ. 1994 Jan 1;308(6920):18-21. doi: 10.1136/bmj.308.6920.18.
4
SARS-CoV-2 and the Angiotensin-Converting Enzyme 2 Receptor: Angiotensin-Converting Enzyme Inhibitor/Angiotensin 2 Receptor Blocker Utilization and a Shift Towards the Renin-Angiotensin-Aldosterone System Classical Pathway.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)与血管紧张素转换酶2受体:血管紧张素转换酶抑制剂/血管紧张素2受体阻滞剂的使用及向肾素-血管紧张素-醛固酮系统经典途径的转变
Cureus. 2024 Mar 5;16(3):e55563. doi: 10.7759/cureus.55563. eCollection 2024 Mar.
5
Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19.血管紧张素转换酶抑制剂、血管紧张素 II 受体阻滞剂与 COVID-19 住院患者结局的关系。
J Am Heart Assoc. 2021 Dec 21;10(24):e023535. doi: 10.1161/JAHA.121.023535. Epub 2021 Dec 10.
6
Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough.中等剂量而非低剂量的阿司匹林可抑制血管紧张素转换酶抑制剂引起的咳嗽。
Am J Hypertens. 2000 Jul;13(7):776-82. doi: 10.1016/s0895-7061(00)00268-5.
7
Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus.血管紧张素转换酶基因插入/缺失,而非缓激肽B2受体-58T/C基因多态性,与中国非胰岛素依赖型糖尿病女性患者中血管紧张素转换酶抑制剂相关性咳嗽有关。
Metabolism. 2001 Nov;50(11):1346-50. doi: 10.1053/meta.2001.27212.
8
Impact of angiotensin-converting enzyme inhibitors or receptor blockers on post-ICU discharge outcome in patients with acute kidney injury.血管紧张素转换酶抑制剂或受体阻滞剂对急性肾损伤患者 ICU 出院后结局的影响。
Intensive Care Med. 2018 May;44(5):598-605. doi: 10.1007/s00134-018-5160-6. Epub 2018 May 15.
9
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂用于患有早期(1至3期)非糖尿病慢性肾病的成人。
Cochrane Database Syst Rev. 2011 Oct 5(10):CD007751. doi: 10.1002/14651858.CD007751.pub2.
10
The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension.新型冠状病毒病(COVID-19)的发生和严重程度与高血压患者使用血管紧张素转换酶抑制剂或血管紧张素 II 受体阻滞剂的关系。
PLoS One. 2021 Mar 18;16(3):e0248652. doi: 10.1371/journal.pone.0248652. eCollection 2021.

本文引用的文献

1
Frequency, Characteristics, and Predictive Factors of Adverse Drug Events in an Adult Emergency Department according to Age: A Cross-Sectional Study.按年龄划分的成人急诊科药物不良事件的发生率、特征及预测因素:一项横断面研究
J Clin Med. 2022 Sep 27;11(19):5731. doi: 10.3390/jcm11195731.
2
Obstacles and Opportunities in Information Transfer Regarding Medications at Discharge - A Focus Group Study with Hospital Physicians.出院时药物信息传递中的障碍与机遇——一项针对医院医生的焦点小组研究
Drug Healthc Patient Saf. 2022 May 17;14:61-73. doi: 10.2147/DHPS.S362189. eCollection 2022.
3
Evaluation of medication risk at the transition of care: a cross-sectional study of patients from the ICU to the non-ICU setting.
医疗护理转换期用药风险评估:一项针对从重症监护病房转至非重症监护病房患者的横断面研究。
BMJ Open. 2022 Apr 15;12(4):e049695. doi: 10.1136/bmjopen-2021-049695.
4
Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema.血管紧张素转化酶抑制剂诱发的血管性水肿。
Emerg Med Clin North Am. 2022 Feb;40(1):79-98. doi: 10.1016/j.emc.2021.09.004. Epub 2021 Oct 29.
5
Angiotensin-Converting Enzyme Inhibitors, Asthma, and Cough: Relighting the Torch.血管紧张素转换酶抑制剂、哮喘与咳嗽:重燃火炬
J Allergy Clin Immunol Pract. 2021 Sep;9(9):3440-3441. doi: 10.1016/j.jaip.2021.07.002.
6
Intolerance to Angiotensin Converting Enzyme Inhibitors in Asthma and the General Population: A UK Population-Based Cohort Study.哮喘和普通人群对血管紧张素转换酶抑制剂的不耐受:一项基于英国人群的队列研究。
J Allergy Clin Immunol Pract. 2021 Sep;9(9):3431-3439.e4. doi: 10.1016/j.jaip.2021.04.055. Epub 2021 May 6.
7
Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on pulmonary function in hypertensive patients.血管紧张素转换酶抑制剂和血管紧张素Ⅱ受体阻滞剂对高血压患者肺功能的比较影响。
J Basic Clin Physiol Pharmacol. 2021 Mar 15;33(2):207-212. doi: 10.1515/jbcpp-2020-0243.
8
ACE2, COVID-19 Infection, Inflammation, and Coagulopathy: Missing Pieces in the Puzzle.血管紧张素转换酶2、新型冠状病毒肺炎感染、炎症与凝血病:拼图中缺失的部分
Front Physiol. 2020 Oct 6;11:574753. doi: 10.3389/fphys.2020.574753. eCollection 2020.
9
Risk for Anaphylactic Reaction from Cardiac Catheterization in Patients Receiving β-Adrenergic Blockers or Angiotensin-Converting Enzyme-Inhibitors.接受β-肾上腺素能阻滞剂或血管紧张素转换酶抑制剂治疗的患者进行心脏导管插入术时发生过敏反应的风险。
J Allergy Clin Immunol Pract. 2020 Jun;8(6):1900-1905. doi: 10.1016/j.jaip.2019.10.020. Epub 2019 Nov 1.
10
Angioedema: a rare and sometimes delayed side effect of angiotensin-converting enzyme inhibitors.血管性水肿:血管紧张素转换酶抑制剂罕见且有时会延迟出现的副作用。
Acta Cardiol. 2019 Aug;74(4):277-281. doi: 10.1080/00015385.2018.1507477. Epub 2018 Oct 17.